Cargando…
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells
BACKGROUND: In the present study, we show that the combination of doxorubicin with the cyclin-dependent kinase inhibitor P276-00 was synergistic at suboptimal doses in the non-small cell lung carcinoma (NSCLC) cell lines and induces extensive apoptosis than either drug alone in H-460 human NSCLC cel...
Autores principales: | Rathos, Maggie J, Khanwalkar, Harshal, Joshi, Kavita, Manohar, Sonal M, Joshi, Kalpana S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635914/ https://www.ncbi.nlm.nih.gov/pubmed/23343191 http://dx.doi.org/10.1186/1471-2407-13-29 |
Ejemplares similares
-
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers
por: Rathos, Maggie J, et al.
Publicado: (2012) -
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines
por: Shirsath, Nitesh P, et al.
Publicado: (2012) -
Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma
por: Mishra, Prabha B, et al.
Publicado: (2013) -
A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells
por: Manohar, Sonal M, et al.
Publicado: (2011) -
Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model
por: Saisomboon, Saowaluk, et al.
Publicado: (2019)